公开(公告)号：US5552267A

公开(公告)日：1996-09-03

申请号：US350319

申请日：1994-12-05

申请人： David M. Stern ,  Mehmet C. Oz ,  Roman Nowygrod ,  Shin Koga ,  David J. Pinsky

发明人： David M. Stern ,  Mehmet C. Oz ,  Roman Nowygrod ,  Shin Koga ,  David J. Pinsky

IPC分类号： A01N1/02

CPC分类号： A01N1/02 ,  A01N1/0226

摘要： An aqueous solution for organ preservation or maintenance, which contains: a vasodilator in an amount sufficient to maintain vascular homeostasis; D-glucose in an amount sufficient to support intracellular function and maintenance of cellular bioenergetics; magnesium ions in an amount sufficient to support intracellular function and maintenance of cellular bioenergetics; macromolecules of molecular weight greater than 20,000 daltons in an amount sufficient to maintain endothelial integrity and cellular viability; potassium ions in a concentration greater than about 110 mM; and a buffer in an amount sufficient to maintain the average pH of the organ preservation or maintenance solution during the period of organ preservation at about physiologic pH or above.

摘要翻译： 用于器官保存或维持的水溶液，其包含：足以维持血管内环境稳定的血管扩张剂; D-葡萄糖的量足以支持细胞内功能和维持细胞生物能量; 足以支持细胞内功能和维持细胞生物能量的镁离子; 分子量大于20,000道尔顿的大分子，其量足以维持内皮完整性和细胞活力; 浓度大于约110mM的钾离子; 以及足以在器官保存期间在约生理pH或以上保持器官保存或维持溶液的平均pH的量的缓冲液。

公开(公告)号：US5049878A

公开(公告)日：1991-09-17

申请号：US336008

申请日：1989-04-10

申请人： David M. Stern

发明人： David M. Stern

IPC分类号： G01F23/26

CPC分类号： G01F23/266

摘要： An improved system for generating a signal representative of the level of a material having a dielectric constant within a vessel is disclosed. The system features use of a first probe for generating a signal indicative of the dielectric constant of the material which is divided into a signal varying with the level of the material whereby a compensated level signal irrespective of the actual dielectric constant is measured. In a preferred embodiment, a single integrator is used to perform the division operation whereby inaccuracies due to component variation including long-term drift are eliminated. The instrument is disclosed as functioning in a two-wire instrument system having low power requirements, permitting use of conventional signal limits. Means for calibrating the instrument in a fail-safe manner such that the operator is assured of proper calibration are disclosed, as is means whereby bridge circuits used to measure in the capacitance measurements supplied to the division circuit are both supplied by a single oscillator means, again increasing reliability and accuracy of the system.

摘要翻译： 公开了一种用于产生代表在容器内具有介电常数的材料的水平的信号的改进的系统。 该系统特征在于使用第一探针来产生指示材料的介电常数的信号，该信号被分成与材料的电平变化的信号，从而测量与实际介电常数无关的补偿电平信号。 在优选实施例中，使用单个积分器来执行除法操作，由此消除由于包括长期漂移的分量变化引起的不准确。 该仪器被公开为在具有低功率要求的双线仪器系统中起作用，允许使用常规信号限制。 公开了以故障安全的方式校准仪器以便确保操作者正确校准的手段，因为用于测量提供给分频电路的电容测量中的桥接电路都由单个振荡器装置提供的手段， 再次提高系统的可靠性和准确性。

公开(公告)号：US4885277A

公开(公告)日：1989-12-05

申请号：US118316

申请日：1987-11-06

申请人： Peter P. Nawroth ,  David M. Stern ,  George D. Wilner

发明人： Peter P. Nawroth ,  David M. Stern ,  George D. Wilner

IPC分类号： C07K14/52 ,  A61K20060101 ,  A61K38/00 ,  A61P7/02 ,  C07K20060101 ,  C07K1/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/485 ,  C07K14/755 ,  C12N9/64

CPC分类号： C07K7/08 ,  C07K14/755 ,  C12N9/6432 ,  C12N9/644 ,  C12Y304/21006 ,  C12Y304/21022 ,  A61K38/00 ,  Y10S514/802 ,  Y10S530/80

摘要： A composition and method for treating thrombotic disorders. The composition comprises a peptide comprising an amino acid sequence corresponding to the sequence of the amino acid residues in the EGF domain of Factor IX, or a subsequence thereof. Such peptides compete with coagulation Factors IX and IXa for endothelial binding cites and thereby inhibit thrombosis formation.

摘要翻译： 用于治疗血栓形成障碍的组合物和方法。 组合物包含一种肽，其包含对应于因子IX的EGF结构域中的氨基酸残基的序列的氨基酸序列或其子序列。 这样的肽与凝血因子IX和IXa竞争内皮结合引物，从而抑制血栓形成。

公开(公告)号：US06228837B1

公开(公告)日：2001-05-08

申请号：US08360821

申请日：1996-10-08

申请人： David M. Stern ,  Matthias Clauss ,  Janet Kao ,  Mark Kayton ,  Steven K. Libutti

发明人： David M. Stern ,  Matthias Clauss ,  Janet Kao ,  Mark Kayton ,  Steven K. Libutti

IPC分类号： A61K3800

CPC分类号： C07K16/24 ,  A61K38/00 ,  C07K14/52

摘要： This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).

摘要翻译： 本发明提供纯化的内皮单核细胞活化多肽（EMAP II）。 它进一步提供了获得纯化的内皮单核细胞活化多肽（EMAP II）的方法，一种制备抗体的方法及其检测方法。 本发明还提供了含有与RIGRIVT同源的氨基酸序列的效应细胞活化蛋白及其检测方法。 本发明还提供了通过施用有效剂量的内皮单核细胞活化多肽（EMAP II）来治疗受试者的肿瘤的方法。

公开(公告)号：US5510779A

公开(公告)日：1996-04-23

申请号：US72608

申请日：1993-06-04

申请人： Frederick L. Maltby ,  L. Jonathan Kramer ,  Leslie D. Horrocks, deceased ,  by Maureen Horrocks, executrix ,  David M. Stern

发明人： Frederick L. Maltby ,  L. Jonathan Kramer ,  Leslie D. Horrocks, deceased ,  by Maureen Horrocks, executrix ,  David M. Stern

IPC分类号： G08C19/02 ,  G08C19/00

CPC分类号： G08C19/02

摘要： An instrument system provides compensation for signal processing errors by processing both sensor signals and reference signals in a common signal processor. Reference signals may be provided which enable zero compensation, gain compensation, or both. The system outputs compensated signals to a two wire signal loop in either analog or digital form, and selects the form of output signal in accordance with digital input signals received from the signal wires. The system may be embodied as a radio frequency admittance instrument system for monitoring the condition of materials.

摘要翻译： 仪器系统通过在公共信号处理器中处理传感器信号和参考信号来提供对信号处理误差的补偿。 可以提供可实现零补偿，增益补偿或两者的参考信号。 系统以模拟或数字形式将补偿信号输出到双线信号回路，并根据从信号线接收的数字输入信号选择输出信号的形式。 该系统可以被实现为用于监视材料状况的射频导纳仪器系统。

公开(公告)号：US08128963B2

公开(公告)日：2012-03-06

申请号：US10679135

申请日：2003-10-03

申请人： David J. Pinsky ,  David M. Stern ,  Charles J. Prestigiacome

发明人： David J. Pinsky ,  David M. Stern ,  Charles J. Prestigiacome

IPC分类号： A61K33/00 ,  A61P9/10

CPC分类号： C12N9/644 ,  A61K38/4846 ,  C07K14/70564 ,  C07K16/2854 ,  C12Y304/21022

摘要： The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

摘要翻译： 本发明提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内以足够量的时间向所述受试者施用药学上可接受的形式的选择素拮抗剂，以防止白细胞积聚，从而治疗缺血性 主题无序。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内向受试者施用足够量的一氧化碳气体，从而治疗受试者的缺血性疾病。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内以足够的时间向受试者施用药学上可接受的形式的灭活因子IX以抑制凝血，以便治疗缺血性障碍 学科。

公开(公告)号：US06969704B1

公开(公告)日：2005-11-29

申请号：US09648389

申请日：2000-08-25

申请人： David Pinsky ,  David M. Stern ,  Shi-Fang Yan

发明人： David Pinsky ,  David M. Stern ,  Shi-Fang Yan

IPC分类号： A01N43/04 ,  A61K31/07 ,  C07H21/04 ,  C12Q1/68

CPC分类号： A61K31/07 ,  C07H21/04

摘要： The invention provides a method for reducing damage to an ischemic tissue which comprises contacting cells of the tissue with an inhibitor of Early Growth Response Factor-1 Protein (Egr-1). In addition, the invention provides a method for reducing vascular injury during reperfusion of an ischemic tissue in a subject which comprises contacting the tissue with a compound which inhibits expression of Early Growth Response Factor-1 (Egr-1) protein in the tissue so as to reduce vascular injury in the tissue during reperfusion. wherein the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5′-CTTGGCCGCTGCCAT-3′ (SEQ ID NO:1). In one embodiment of the invention, the subject has suffered a stroke, or a myocardial infarction. In another embodiment of the invention, the subject is undergoing or has undergone angioplasty, cardiac surgery, vascular surgery, or organ transplantation.

摘要翻译： 本发明提供了减少对缺血组织的损伤的方法，其包括使组织的细胞与早期生长反应因子-1蛋白（Egr-1）的抑制剂接触。 此外，本发明提供了减少受试者缺血组织再灌注期间的血管损伤的方法，其包括使组织与抑制组织中早期生长反应因子-1（Egr-1）蛋白表达的化合物接触，以便 以减少再灌注期间组织中的血管损伤。 其中所述抑制剂是基本上由多核苷酸序列5'-CTTGGCCGCTGCCAT-3'（SEQ ID NO：1）组成的核酸。 在本发明的一个实施方案中，受试者患有中风或心肌梗死。 在本发明的另一个实施方案中，受试者正在或已经进行血管成形术，心脏手术，血管外科手术或器官移植。

公开(公告)号：US06734168B2

公开(公告)日：2004-05-11

申请号：US09851026

申请日：2001-05-07

申请人： David M. Stern ,  Matthias Clauss ,  Janet Kao ,  Mark Kayton ,  Steven K. Libutti

发明人： David M. Stern ,  Matthias Clauss ,  Janet Kao ,  Mark Kayton ,  Steven K. Libutti

IPC分类号： A61K3800

CPC分类号： C07K16/24 ,  A61K38/00 ,  C07K14/52

摘要： The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.

摘要翻译： 本发明提供纯化的内皮单核细胞活化多肽II，其中所述多肽具有约20,000道尔顿的表观分子量。 本发明还提供了一种效应细胞活化蛋白，其包含具有氨基酸序列的多肽，其中至少四个氨基酸残基与RIGRTVT相同并且处于相同的相对位置。 本发明还提供编码效应细胞活化蛋白的DNA。 本发明还提供了在受试者中诱导炎症的方法和治疗受试者肿瘤的方法。 本发明还提供了包含内皮单核细胞活化多肽II和载体的药物组合物。

公开(公告)号：US5728705A

公开(公告)日：1998-03-17

申请号：US131984

申请日：1993-10-04

申请人： Charles A. Lawson ,  David J. Pinsky ,  Arthur Smerling ,  David M. Stern

发明人： Charles A. Lawson ,  David J. Pinsky ,  Arthur Smerling ,  David M. Stern

IPC分类号： A61K31/13 ,  A61K31/195 ,  A61K31/21 ,  A61K31/295 ,  A61K31/40 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/52 ,  A61K61/70 ,  A61K31/33 ,  C07D473/00 ,  C07H19/20

CPC分类号： A61K31/70 ,  A61K31/13 ,  A61K31/195 ,  A61K31/21 ,  A61K31/295 ,  A61K31/40 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/52 ,  Y10S514/851

摘要： This invention provides a method of selectively decreasing pulmonary vascular resistance in a subject by administering endobronchially a drug chosen from among cAMP analogs, cGMP analogs, phosphodiesterase inhibitors, nitric oxide precursors, nitric oxide donors, and nitric oxide analogs.

摘要翻译： 本发明提供了一种通过内源性施用选自cAMP类似物，cGMP类似物，磷酸二酯酶抑制剂，一氧化氮前体，一氧化氮供体和一氧化氮类似物的药物来选择性降低受试者的肺血管阻力的方法。

公开(公告)号：US5426097A

公开(公告)日：1995-06-20

申请号：US45261

申请日：1993-04-06

申请人： David M. Stern ,  Keisuke Kuwabara ,  Claude Benedict ,  Jane Ryan

发明人： David M. Stern ,  Keisuke Kuwabara ,  Claude Benedict ,  Jane Ryan

IPC分类号： A61K38/00 ,  C07K14/47 ,  A61K35/42

CPC分类号： C07K14/4702 ,  C07K14/4725 ,  A61K38/00 ,  Y10S530/848

摘要： The subject invention provides a pharmaceutical composition, which comprises an amount of calreticulin effective for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, and a pharmaceutically effective carrier. The subject invention provides a method for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, which method comprises administering calreticulin to the subject in an amount effective for blocking or preventing thrombosis. The subject invention provides a pharmaceutical composition, which comprises calreticulin in combination with an other antithrombotic agent, in an amount and proportion effective for enhancing the action of the other antithrombotic agent, to prevent clotting or dissolve clots which have already formed. The subject invention provides a method for enhancing the action of an other antithrombotic agent which prevent clotting or dissolve clots which have already formed, comprising administering to a subject calreticulin in combination with the other antithrombotic agent in an amount and proportion for enhancing the action of the other antithrombotic agent, to prevent clotting or dissolve clots which have already formed.

摘要翻译： 本发明提供一种药物组合物，其包含有效阻断或预防受试者血栓形成的钙网蛋白的量，在正常止血中基本上不引起缺陷或无缺陷，以及药学上有效的载体。 本发明提供了一种用于阻断或预防受试者血栓形成的方法，在正常止血中基本上不引起缺陷或无缺陷，所述方法包括以有效阻断或预防血栓形成的量向患者施用钙网蛋白。 本发明提供了一种药物组合物，其包含与其它抗血栓形成剂组合的钙网蛋白，其量和比例对于增强其它抗血栓形成剂的作用有效，以防止凝血或溶解已经形成的凝块。 本发明提供了一种用于增强其它抗血栓形成剂的作用的方法，所述其它抗血栓形成剂预防凝血或溶解已经形成的凝块，其包括与受试者钙网蛋白联合用于其它抗血栓形成剂的量和比例，以增强其作用 其他抗凝血剂，以防止凝血或溶解已经形成的凝块。